These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10532865)

  • 1. IMpact-RSV Study Group report.
    Zempsky WT; Schechter NL
    Pediatrics; 1999 Oct; 104(4 Pt 1):993-4; author reply 995. PubMed ID: 10532865
    [No Abstract]   [Full Text] [Related]  

  • 2. IMpact-RSV Study Group report.
    Fox JL
    Pediatrics; 1999 Oct; 104(4 Pt 1):994-5. PubMed ID: 10532866
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
    Winchester L; García L; García I; Concepción CB
    P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetracaine (ametop) compared to placebo for reducing pain associated with intramuscular injection of palivizumab (synagis).
    Newby BD; Faschoway GD; Soukoroff CI
    J Pediatr Nurs; 2009 Dec; 24(6):529-33. PubMed ID: 19931151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
    DeVincenzo JP; Aitken J; Harrison L
    J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T
    J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recommendations for immunologic prevention of respiratory syncytial virus (RSV) infections].
    Z Geburtshilfe Neonatol; 1999 Dec; 203 Suppl 2():16. PubMed ID: 10612193
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guidelines for respiratory syncytial virus prophylaxis. An update].
    Carbonell-Estrany X; Quero Jiménez J
    An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus infections: recent prospects for control.
    Sidwell RW; Barnard DL
    Antiviral Res; 2006 Sep; 71(2-3):379-90. PubMed ID: 16806515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).
    National Advisory Committee on Immunization
    Can Commun Dis Rep; 2003 Sep; 29():1-15. PubMed ID: 14524195
    [No Abstract]   [Full Text] [Related]  

  • 16. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
    Cox RA; Rao P; Brandon-Cox C
    J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus infections: characteristics and treatment.
    Chidgey SM; Broadley KJ
    J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Give Synagis via home health.
    Goldenring J
    Pediatrics; 2007 Jan; 119(1):219. PubMed ID: 17200293
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.